Tiba is a pre-clinical stage company founded in 2018 based on 5 years of research on RNA delivery at MIT’s Whitehead and Koch Institutes. We develop RNA vaccines and therapeutics based on a novel nanoparticle technology that can package large nucleic acid payloads with lower inflammatory side effects than current lipid nanoparticle (LNP) technologies. Our proprietary ‘RNABL’ platform is based on a class of biodegradable dendrimer molecules that form highly dense and stable nanoparticles that avoid unwanted uptake in the liver, enabling therapeutic applications in a wider variety of target tissues. With a large library of proprietary RNABL molecules, Tiba scientists can tune RNA delivery to different tissues and cells to suit a particular application. Because RNABL nanoparticles induce lower inflammation than LNPs, Tiba can develop safer medicines with less dose-limiting side effects. In addition to venture funding, we have secured support from the NIH, CEPI, and most recently BARDA.